Search: Analyst Coverage

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Earns Coverage for DehydraTECH(TM)’s Potential Market Reach, Multiple Uses

Lexaria Bioscience Corp. (NASDAQ: LEXX) was recently part of coverage by Zacks Small-Cap Research analysts based on its market potential. Zacks, which focuses its coverage on small and micro-cap companies it regards as under-followed or under-valued by the broader market in an effort to benefit investors as well as worthy innovators, valued the company at $15 per share. The valuation…

Lexaria Bioscience Corp. (NASDAQ: LEXX) Oral Drug Use Technology Nets Zacks Research Coverage

Zacks Small-Cap Research analysts recently announced coverage of Lexaria based on its market potential, valuing the company at $15 per share Lexaria’s patented DehydraTECH(TM) technology is undergoing clinical and pre-clinical trials for potential use in treating hypertension, viral infections and other conditions that are currently being addressed through cannabidiol-based nutraceuticals or prescription drugs Lexaria is also investigating alternatives to smoked…

Cannabis Retailer Kiaro Initiates Analyst Reporting With Fundamental Research Corp.

Kiaro Holdings Corp. (TSXV: KO) (“Kiaro” or the “Company”), a national omni-channel cannabis retailer and wholesale distributor, is pleased to announce that the Company has initiated analyst coverage with Fundamental Research Corp (FRC) an independent small-cap research specialist firm located in Vancouver, B.C. Kiaro’s initial research report and future reports may be obtained directly from FRC. The opinions expressed in this report are the…

Here are analysts’ favorite marijuana stocks, which they expect to rise as much as 82% in the next year

Marijuana stocks have surged this year as investors anticipate wider acceptance of legal distribution of recreational products in the U.S. Your best way to ride this wave may be through exchange traded funds. Recent coverage includes efforts by Senate Majority Leader Chuck Schumer to introduce legislation for the federal legalization of marijuana and New York Gov. Andrew Cuomo’s drive toward…

Aurora Cannabis Analyst Says Stock Will Go Up In Smoke, Sets Zero Price Target

Aurora Cannabis Inc (NYSE: ACB) shares were burning up Monday after a sell-side analyst took the most bearish stance possible on the Canadian company’s stock. GLJ Research analyst Gordon Johnson initiated coverage of Aurora Cannabis with a Sell rating and zero price target. Aurora Cannabis’ equity is effectively worthless, Johnson said in the Monday initiation note. READ MORE: https://finance.yahoo.com/news/aurora-cannabis-analyst-says-stock-213011564.html?.tsrc=rss

‘We are calling the bottom’: Analyst sees brighter outlook for pot stocks

A New York-based analyst says Canada’s cannabis sector has bottomed out, predicting several positive events in the coming year should catalyze pot stocks as valuations trade at two-year lows. Cantor Fitzgerald Analyst Pablo Zuanic, who initiated coverage of six cannabis stocks Monday, said in a report to clients that several pot companies are attractive at current levels based on the…